THE BLOOM of HEMP Emerging Opportunities in Food, Wellness + Personal Care PRESENTERS

Total Page:16

File Type:pdf, Size:1020Kb

THE BLOOM of HEMP Emerging Opportunities in Food, Wellness + Personal Care PRESENTERS THE BLOOM OF HEMP Emerging Opportunities in Food, Wellness + Personal Care PRESENTERS LORA LASSLEY • VP, Product Development, Ecofibre Limited • 20 year veteran in the beauty industry with the majority of her career at Dermalogica • Passionate about blending premium hemp extract with classic skincare ingredients, newly discovered botanical extracts, and the latest advancements in sustainable chemistry DR. ALEX CAPANO, DNP, CRNP, FNP-BC • Chief Science Officer, Ecofibre Limited • First doctoral candidate of any discipline who focused on cannabinoid science • Champions Ecofibre’s IRB-approved and FDA-approved research programs to advance the clinical evidence of hemp extract HEMP 101 Cannabis with 0.3% or less THC by weight WHAT ARE CANNABINOIDS? • Organic molecules that interact with or effect the body’s endocannabinoid system (ECS) • Over 100 cannabinoids identified; Abundant in cannabis plants, some other sources exist • Synthetic vs. Plant-derived LEGALITY SUSTAINABILITY • 2018 Farm Bill Insights • Can be farmed without pesticides • Federally legal in the U.S. • No excess water requirements • Emerging global market • No need for fallow fields WHAT IS CBD? • CBD = cannabidiol • Benefits without intoxication • Future role for minor cannabinoids ECOFIBRE’S FULL SPECTRUM HEMP EXTRACT CANNABINOID PROFILE HEMP PLANT ARCHITECTURE FLOWERS • Hemp extract, “CBD oil” • Types of products: topicals, ingestibles • Full Spectrum vs. Broad Spectrum vs. Isolate Hemp Extract SEEDS • Food: Hemp seed oil, flour, protein, omega opportunity HURD • Textiles THE HEMP TODAY TOMORROW Global market: US CBD market: Estimates + CBD MARKET $9.6B in 2020 $15B USD by 2025 to >$20 (source: Grandview Research) billion by 2024 (Sources: Cowen & Co. Investment Bank, BDS analytics, Arcview Market Research) Global estimate: $89B USD by 2026 (source: Global Market Insights) Health & Beauty ONLY: $3B US by 2024 (Source: Market Reports World as seen in Cosmetic and Toiletries –9/02/20) REGULATORY PARAMETERS • Farm Bill expiration in October 2021 - what does this mean for the future of Cannabinoids? • FDA Monograph potential • Pharmacists are embracing CBD products for both ingestion and topical use, will the FDA? • State imposed restrictions REGULATORY CLAIMS DOSING PARAMETERS:DO • Cannot make claims on • “Suggested Use” OK s +DON’Ts CBD alone • Dosing directions too risky • Must combine with other • Packaging & Transparency ingredient PACKAGING • Work with a reputable partner who knows what should be on the label • What is required varies by state distribution OUR COMMITMENT TO ADVANCING THE CLINICAL EVIDENCE OF HEMP EXTRACT AND FORMULATIONS BACKED BY SCIENCE OPIOID STUDY • Over 50% of participants reduced opioids in 8 weeks • 94% of participants reported improved quality of life • Statistically significant improvements in sleep and pain (CI 95%) CIPN & ALZHEIMER’S STUDIES (ONGOING) • Phase II Clinical Trials • DMF and IND with FDA • Outcomes measured: Pain, Sleep, Agitation, Anxiety, Caregiver Burden ENDOMETRIOSIS, SUBSTANCE USE DISORDERS, AND SKINCARE SITES OF CANNABINOID RECEPTORS IN SKIN AND IMMUNE CELLS Copyright Metabeauty 2019 WHY ANANDA FULL SPECTRUM HEMP EXTRACT FOR SKINCARE? 1. Promotes cell turnover which prevents wrinkles and improves appearance of fine lines 2. Reduces erythema via anti-inflammatory mechanisms 3. Deep moisturizing agent 4. Halts proliferation of unhealthy or infected cells; promotes necessary apoptosis (boosts complexion and prevents wrinkles) 5. Potent anti-inflammatory agent, reducing puffiness, redness and preventing the development of fine lines 6. Kills P. acnes bacteria at concentrations of 0.4% 2. Is sebostatic and promotes anti-proliferative and anti- inflammatory effects on human sebocytes 7. Does NOT contribute to antimicrobial resistance of P. acnes; all current topical anti-acne antimicrobials risk resistance. To avoid this, they need to be used concurrently with benzoyl peroxide, a substance that is irritating, drying, and often carries an unpleasant odor. It also risks bleaching skin, pillows, and clothing. Ananda offers an alternative solution to kill without bacterial resistance risk and need for use of harsh chemicals like benzoyl peroxide. 8. Formula can act against other major pathogenic features of acne, including lipogenesis, proliferation and inflammation through distinct molecular pathways. WHY ANANDA FULL SPECTRUM HEMP EXTRACT FOR BODY CARE? 1. Anti-inflammatory properties improve source of pain and aid in muscle recovery 2. Anti-nociceptive properties of Ananda extract reduce perception of pain 3. Immunomodulation via multiple mechanisms, including reducing histamine release from mast cells, alleviate inflammatory skin conditions (i.e. atopic dermatitis, psoriasis, eczema, rheumatoid arthritis, insect bite reactions, etc.) 4. Calms irritation ANTIMICROBIAL RESEARCH 1. >99.9% bactericidal on multiple pathogens • Staph (MSSA), MRSA, Streptococcus, P. acnes 2. Serial passage study: No risk of antimicrobial resistance HEMP FOOD OVERVIEW • Complete plant protein that’s easily digestible (2 main protein are edestin and albumin) • Omega 3 and 6 fatty acids in same ratio as our bodies • High in fiber and low in sugars • Good source of plant-based iron, magnesium WHAT TO CONSIDER WHEN RESEARCHING HEMP PARTNERS QUESTIONS TO ASK – HEMP EXTRACT SUPPLIERS IMPORTANCE OF SUPPLY CHAIN QUALITY CONTROL 1. Who and where is your supplier? 1. Does the supplier offer 3rd party testing for pesticides, residual solvents, heavy metals, 2. What are their farming and manufacturing aflatoxins? standards? 2. At what points? 3. What is their grower(s) knowledge and experience? 3. Assay confirmation - Did you get what you ordered? 4. Crops location, soil quality, harvest timing? 4. What is the consistency of products? Any 5. What is the extraction and manufacturing standardization methods? process? 6. How much transparency and traceability do HEMP EXPERTISE they offer to partners and end consumers? At what points of supply chain? 1. Can they validate answers with research? 2. What are their relationships with regulatory authorities? 3. Can they offer formulation support? COA Sample REQUEST A CERTIFICATE OF ANALYSIS …then question it. QUESTIONS TO ASK – HEMP FOOD SUPPLIERS 1. Where is your hemp coming 4. How long is the hemp dehulled? from? 5. How are the end products packaged to 2. Is the supplier BRCGS preserve the nutritional profile? approved? 6. What testing is completed? Hemp is a 3. How quickly is the hemp dried bio accumulator – if there are heavy once it is harvested? metals in the soil the plant will absorb them. This is why it is important to select where you grow and follow up with testing to verify WHO IS GOING TO MAKE IT IN HEMP AND CBD MARKET? • Success ultimately comes down to identifying a quality supplier • If your CBD is not high quality and consistent, consumers won’t see results • Secure loyal customers by producing products that work • Avoid risks and protect your business with safe, compliant suppliers. NEXT STEPS • Ask a question! • Request a sample through UL Prospector • Meet with the Ecofibre team to discuss bulk and white label opportunities.
Recommended publications
  • Special Report on ASX-Listed Cannabis and Hemp Stocks
    Special Report on ASX-listed Cannabis and Hemp stocks An exciting new sector 24 March 2020 From humble beginnings in Canada around ten years ago the cannabis and hemp industries have blossomed into a major force to be reckoned with by investors the world over. Australia is no exception, with many cannabis and hemp companies having gone live on ASX over the last five years. However, many investors are unfamiliar with the dynamics of this exciting new sector. Pitt Street Research now seeks to close that information gap with our Special Report on Cannabis and Hemp, released 24 March 2020. Welcome to the cannabis and hemp revolution Cannabis and hemp have fuelled a major investment boom since 2014 largely because of the known therapeutic benefits of medicinal cannabis. Governments around the world have responded to the scientific evidence and made it easier for patients to access cannabis-based medicine. Concurrently, voters in many countries have become more favourably disposed towards the legalisation of recreational cannabis. These two trends have fuelled a boom in cannabis, while hemp, from a different plant, had also benefited as investors have moved to use this plant for a variety of purposes, most notably in food. It’s fair to say that cannabis and hemp have quickly become respectable industries worthy of investor attention. Many have come to the view that cannabis and hemp are agents of serious economic change, with potential to seriously disrupt Subscribe to our research HERE sectors as diverse as drinks, building materials and, of course, medicine. Analyst: Stuart Roberts Why should the Canadians have all the fun? Tel: +61 (0)447 247 909 Canada was the origin of the current cannabis and hemp boom because the regulatory framework changed in that [email protected] country around 2013 in a way that allowed entrepreneurs to flourish while the public equity markets allowed large amounts of capital to be raised.
    [Show full text]
  • 11-05-18 DRAFT 4:41 PM UTAH MEDICAL CANNABIS ACT 1 2018 THIRD SPECIAL SESSION 2 STATE of UTAH 3 4 LONG TITLE 5 General Descript
    11-05-18 DRAFT 4:41 PM 1 UTAH MEDICAL CANNABIS ACT 2 2018 THIRD SPECIAL SESSION 3 STATE OF UTAH 4 5 LONG TITLE 6 General Description: 7 This bill provides for the cultivation, processing, medical recommendation, and patient use of 8 medical cannabis. 9 Highlighted Provisions: 10 This bill: 11 ▸ defines terms; 12 ▸ provides for licensing and regulation of a cannabis cultivation facility, a 13 cannabis processing facility, an independent cannabis testing laboratory, and a 14 medical cannabis pharmacy; 15 ▸ provides for security and tracking of medical cannabis and a medical cannabis 16 product from cultivation to consumptionuse to ensure safety and chemical content; 17 ▸ requires certain labeling and childproof packaging of medical cannabis and a 18 medical cannabis product; 19 ▸ requires the Department of Agriculture and Food, the Department of Health, the 20 Department of Public Safety, and the Department of Technology Services to create 21 an electronic verification system to facilitate recommendation, dispensing, and 22 record-keeping for medical cannabis transactions; 23 ▸ allows an individual with a qualifying condition to obtain a medical cannabis 24 patient card on the recommendation of a certain medical professional to gain access 25 to medical cannabis; 26 ▸ allows a patient to designate a caregiver to assist with accessing medical 27 cannabis; 28 ▸ provides thatfor a parent or legal guardian isto obtain a medical cannabis 29 guardian card for an eligible minor patient and for the designated caregiver for a 30 minorminor patient
    [Show full text]
  • Personal Use Cannabis Rules Special Adopted New Rules: N.J.A.C
    NEW JERSEY CANNABIS REGULATORY COMMISSION Personal Use Cannabis Rules Special Adopted New Rules: N.J.A.C. 17:30 Adopted: August 19, 2021 by New Jersey Cannabis Regulatory Commission, Dianna Houenou, Chair. Filed: August 19, 2021 Authority: N.J.S.A. 24:6I-31 et seq. Effective Date: August 19, 2021 Expiration Date: August 19, 2022 This rule may be viewed or downloaded from the Commission’s website at nj.gov/cannabis. These rules are adopted pursuant to N.J.S.A. 24:6I-34(d)1a of the New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act, N.J.S.A. 24:6I- 31 et seq., and became effective upon acceptance for filing by the Office of Administrative Law. The specially adopted new rules shall be effective for a period not to exceed one year from the date of filing of the new rules, that is, until August 19, 2022. The Commission has provided this special adoption to the Attorney General, State Treasurer, Commissioner of Health, and Commissioner of Banking and Insurance for a consultation period, after which the Commission anticipates filing a proposal to readopt these rules with amendments reflecting the results of that consultation. In accordance with N.J.S.A. 24:6I-34(d)1b the rules, as readopted, will become effective upon acceptance for filing by the Office of Administrative Law if filed on or before the expiration date of the rules published herein. The adopted amendments will be effective upon publication in the New Jersey Register. Federal Standards Analysis The Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act obliges the Cannabis Regulatory Commission to promulgate rules necessary or proper to enable it to carry out the Commission’s duties, functions, and powers with respect to overseeing the development, regulation, and enforcement of activities associated with the personal use of cannabis pursuant to P.L.2021, c.16.
    [Show full text]
  • Healing Herb Fitness High Stress Less
    CENTENNIAL SPOTLIGHT CENTENNIAL SPOTLIGHT ® ® WOMEN WEED™ STRESS& LESS HEALING HERB Discover the Marijuana's Calm of CBD Medical Miracles COVID-19 FITNESS HIGH Why the Plant How THC WOMEN & WEED & WOMEN Can Help Boosts Workouts ™ PLUS Is Cannabis CENTENNIAL SPECIALS the Female Viagra? Display Until 4/26/21 $12.99 CENTENNIAL SPOTLIGHT CENTENNIAL SPOTLIGHT ® ® WOMEN WEED™ STRESS& LESS HEALING HERB Discover the Marijuana's Calm of CBD Medical Miracles COVID-19 FITNESS HIGH Why the Plant How THC WOMEN & WEED & WOMEN Can Help Boosts Workouts ™ PLUS Is Cannabis CENTENNIAL SPECIALS the Female Viagra? Display Until 4/26/21 $15.99 CENTENNIAL SPOTLIGHT® WOMEN &WEED™ 2 WOMEN & WEED 3 SECTION 1 34 CANNABIS PRIMER 8 News of the Weed World 14 Words of Weed 54 EDITOR’S LETTER 16 Terpenes & Cannabinoids 20 Seven Studies to Know Now So 2020 was … well, it was 24 State of Disunion something. Between the 28 What’s Legal Where COVID-19 pandemic, murder You Live hornets, civil unrest and an election like no other, it’s no wonder so many of us are SECTION 2 excited to dive headfirst into 2021. And things are looking HEALTH AND WELLNESS good…at least on the cannabis 34 The Wonder Weed front. In this issue, we’ll talk 40 CBD and Stress about how weed won big in the 44 Could CBD Be the November elections, with five Female Viagra? states passing measures to 46 Weed With Your Workout legalize medical or adult-use marijuana and more soon to 50 When Pot Isn’t 28 follow, plus what the Biden Working for You administration means for federal legalization.
    [Show full text]
  • A Belated Green Revolution for Cannabis: Virtual Genetic Resources to Fast-Track Cultivar Development
    REVIEW published: 29 July 2016 doi: 10.3389/fpls.2016.01113 A Belated Green Revolution for Cannabis: Virtual Genetic Resources to Fast-Track Cultivar Development Matthew T. Welling 1, Tim Shapter 1, 2, Terry J. Rose 1, Lei Liu 1, Rhia Stanger 1 and Graham J. King 1* 1 Southern Cross Plant Science, Southern Cross University, Lismore, NSW, Australia, 2 Ecofibre Industries Operations Pty Ltd, Maleny, QLD, Australia Cannabis is a predominantly diecious phenotypically diverse domesticated genus with few if any extant natural populations. International narcotics conventions and associated legislation have constrained the establishment, characterization, and use of Cannabis genetic resource collections. This has resulted in the underutilization of genepool variability in cultivar development and has limited the inclusion of secondary genepools associated with genetic improvement strategies of the Green Revolution. The structured screening of ex situ germplasm and the exploitation of locally-adapted intraspecific traits is expected to facilitate the genetic improvement Edited by: Jaime Prohens, of Cannabis. However, limited attempts have been made to establish the full extent of Polytechnic University of Valencia, genetic resources available for pre-breeding. We present a thorough critical review of Spain Cannabis ex situ genetic resources, and discuss recommendations for conservation, Reviewed by: pre-breeding characterization, and genetic analysis that will underpin future cultivar Ryan C. Lynch, University of Colorado Boulder, USA development. We consider East Asian germplasm to be a priority for conservation Giuseppe Mandolino, based on the prolonged historical cultivation of Cannabis in this region over a range Council for Agricultural Research and Economics, Italy of latitudes, along with the apparent high levels of genetic diversity and relatively *Correspondence: low representation in published genetic resource collections.
    [Show full text]
  • Effective 12/3/2018 Superseded 3/26/2019 4-41A-701 Cannabis and Cannabis Product Testing. (1) a Medical Cannabis Pharmacy and Th
    Utah Code Effective 12/3/2018 Superseded 3/26/2019 4-41a-701 Cannabis and cannabis product testing. (1) A medical cannabis pharmacy and the state central fill medical cannabis pharmacy may not offer any cannabis or cannabis product for sale unless an independent cannabis testing laboratory has tested a representative sample of the cannabis or cannabis product to determine: (a) (i) the amount of total composite tetrahydrocannabinol and cannabidiol in the cannabis or cannabis product; and (ii) the amount of any other cannabinoid in the cannabis or cannabis product that the label claims the cannabis or cannabis product contains; (b) that the presence of contaminants, including mold, fungus, pesticides, microbial contaminants, heavy metals, or foreign material, does not exceed an amount that is safe for human consumption; and (c) for a cannabis product that is manufactured using a process that involves extraction using hydrocarbons, that the cannabis product does not contain a level of a residual solvent that is not safe for human consumption. (2) By rule, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the department: (a) may determine the amount of any substance described in Subsections (1)(b) and (c) that is safe for human consumption; and (b) shall establish protocols for a recall of cannabis or a cannabis product by a cannabis production establishment. (3) The department may require testing for a toxin if: (a) the department receives information indicating the potential presence of a toxin; or (b) the department's inspector has reason to believe a toxin may be present based on the inspection of a facility.
    [Show full text]
  • FDA Office of Women's Health US Food and Drug Administration
    FDA OFFICE OF WOMEN’S HEALTH SCIENTIFIC CONFERENCE CBD & Other Cannabinoids Sex and Gender Differences in Use and Responses Thursday, November 19, 2020 | 9:00 AM–4:00 PM EST Virtual Meeting CBD and Other Cannabinoids: Sex and Gender Differences in Use and Responses | 1 !/"'""'', 11 U.S. FOOD & DRUG •J ADMINISTRATION Dear Colleagues, On behalf of the U.S. Food and Drug Administration's (FDA) Office of Women's Health (OWH), I am pleased to welcome you to today's conference, "CBD and Other Cannabinoids: Sex and Gender Differences in Use and Responses." The mission of FDA is to protect and promote public health. A top priority for OWH is to identify and monitor emerging areas of interest and potential concern for the health of women. Cannabidiol (CBD) products are appearing everywhere - from medical cannabis dispensaries, to pharmacies, to gas stations. Many of these products are illegally marketed and purport to target a myriad of health concerns, including conditions more commonly experienced by women than men, such as chronic pain, sleep disturbances, anxiety and depression. Given that little is known about how and if many cannabis­ derived products work, how and why women are using them, and their potential associated risks, there is a mounting need to consolidate and communicate what we know about these products and to identify knowledge gaps. Further, the use of these products during pregnancy and lactation raises additional questions and concerns. The purpose of today's meeting is to highlight the needed and existing research to address the many "who", "what", and "why" questions surrounding products containing CBD and other cannabinoids.
    [Show full text]
  • EOF 2019 AGM Speeches
    ASX ANNOUNCEMENT ASX: EOF ____________________________ 14 November 2019 Ecofibre Limited Annual General Meeting Speeches Ecofibre Limited (Ecofibre, Company) (ASX:EOF, OTC – Nasdaq Intl Designation: EOFBF) Please find attached the Chairman and Managing Director addresses, and the accompanying slides, to be presented at Ecofibre Limited’s Annual General Meeting today in Sydney. Jonathan Brown Company Secretary 1 ASX ANNOUNCEMENT Investor Relations and Media please contact: Jonathan Brown, Company Secretary, Ecofibre Limited Level 12, 680 George Street, Sydney NSW 2000 [email protected] About Ecofibre Ecofibre is a provider of hemp products in the United States and Australia. In the United States, the Company produces nutraceutical products for human and pet consumption, as well as topical creams and salves. See www.anandahemp.com and www.anandaprofessional.com. In Australia, the Company produces 100% Australian grown and processed hemp food products including protein powders, de-hulled hemp seed and hemp oil. See www.anandafood.com. The Company is also developing innovative hemp-based products in textiles and composite materials in partnership with Thomas Jefferson University (TJU) in the United States. See www.hempblack.com. The Company owns or controls key parts of the value chain in each business, from breeding, growing and production to sales and marketing. Our value proposition to customers is built on strong brands and quality products. Authorisation This document is authorised to be given to the Australian Securities Exchange (ASX) by Eric Wang, Managing Director. 2 Ecofibre Limited Annual General Meeting Thursday, 14 November 2019 Chairman and Managing Director’s Address Chairman’s Address Ecofibre listed on the ASX on 29 March 2019 at a price of $1.00 per share and a total value of just over $300m.
    [Show full text]
  • Overview of the WSLCB Rule Development Process Sara Cooley Broschart
    Overview of the WSLCB Rule Development Process Kathy Hoffman, MPA, MALC Policy and Rules Manager Washington State Liquor and Cannabis Board Prevention Summit November 4, 2020 Presentation Outline Today’s Presentation • WSLCB rule development process, including: • What does the WSLCB do? • Rule development process • From concept to completion • How to get involved • Statutory and regulatory authority • The most effective ways to provide input and comment • Current Rule Projects and Future Rule Projects Presentation Outline Who is WSLCB and what does WSLCB do? • Three-person Board • License liquor, cannabis, vapor and tobacco product production, processing and product sale. Presentation Outline Rule Development Process Basic Rule Making Process The standard rule making process is described in chapter 34.05 RCW, the Administrative Procedures Act, and divided into three stages: • Stage 1: Pre-proposal Statement of Inquiry (CR-101) – RCW 34.05.310 • Stage 2: Proposed Rule Making (CR-102) - RCW 34.05.320 • State 3: Rule-making Order (CR-103) - RCW 34.05.360 Each stage consists of specific tasks and processes. Start CR-101 Pre-proposal . Statement of Inquiry CR-102 Proposal Public Hearing: Oral Testimony Written Testimony Stakeholder Engagement: Listen and Learn Forums Draft Conceptual Rule Workshops DeliBerative Dialogue Sessions CR-103 Final Agency Responds Adoption to Comments Rule development, drafting, Finish and analysis Standard Rule Making – Stage 1 Pre-Proposal Statement of Inquiry (CR-101) – RCW 34.05.310 Purpose: Describes the issue(s) being considered for rule development • The CR-101 identifies the purpose and scope of rulemaking. • The scope of the rules created through this process is controlled by statutory authority and must be compatible with existing requirements.
    [Show full text]
  • What Is in the Law Public Health and Safety
    What is in the Law Public Health and Safety Overview On March 31, 2021, New York State legalized adult-use cannabis (also known as marijuana, or recreational marijuana) by passing the Marijuana Regulation & Taxation Act (MRTA). The legislation creates a new Office of Cannabis Management (OCM) governed by a Cannabis Control Board to oversee and implement the law (collectively referred to as the “OCM”). The OCM will issue licenses and develop regulations outlining how and when business can participate in the new industry. The OCM will also oversee the State’s existing Medical Marijuana and Cannabinoid Hemp Programs. The information below is a collection of key provisions from the MRTA that are intended to help protect the public health and safety of New Yorkers. For additional information, or to contact the Office of Cannabis Management (OCM), please visit our website at: www.cannabis.ny.gov or e-mail us at: [email protected]. Benefits of Regulation One of the main benefits of legalizing adult-use cannabis is that cannabis products will be regulated under a framework that protects consumer health and safety, similar to many other products humans consume. The OCM will be implementing quality assurance regulations, governing the manufacturing, packaging, labeling, advertising, and testing of cannabis products. The OCM will also be conducting a robust public health and education campaign, to monitor and track the impact of adult-use cannabis legalization on public health and safety indicators and to implement regulations that protect vulnerable populations and prohibit the marketing and advertising of cannabis to youth. In addition, 20% of all adult-use cannabis tax revenue is dedicated to public health education and substance-use prevention programs.
    [Show full text]
  • Understanding Cannabinoid Analytics
    A Primer on the Process of Cannabinoids Derived Through Biosynthesis Understanding Cannabinoid Analytics New York, Toronto | LAVVAN.com | 1-888-528-8261 The United States Food and Drug Administration currently prohibits the addition of CBD to food and dietary supplement product This is a confidential document. Do not distribute. Table of Contents Introduction ....................................................................................................................... 3 The Current State of Cannabinoid Product Testing ........................................................ 3 Analytical Targets in Cannabis Products ......................................................................... 5 Cannabinoids ............................................................................................................................. 5 Water Content ............................................................................................................................ 6 Terpenes .................................................................................................................................... 6 Microbial Contamination ............................................................................................................ 6 Endogenous Contaminants: Residual Solvents, Heavy Metals, and Pesticides ...................... 7 Defining the Analytical Testing Process .......................................................................... 7 Sampling of the Product Material..............................................................................................
    [Show full text]
  • A Baseline Review and Assessment of the Massachusetts Adult-Use Cannabis Industry: Market Data and Industry Participation
    A Baseline Review and Assessment of the Massachusetts Adult-Use Cannabis Industry: Market Data and Industry Participation February 2020 Massachusetts Cannabis Control Commission: Steven J. Hoffman, Chairman Kay Doyle, Commissioner Jennifer Flanagan, Commissioner Britte McBride, Commissioner Shaleen Title, Commissioner Shawn Collins, Executive Director Prepared by the Massachusetts Cannabis Control Commission Research and Information Technology Departments: Samantha M. Doonan, BA, Research Analyst David McKenna, PhD, Chief Technology Officer Julie K. Johnson, PhD, Director of Research Acknowledgements External Collaborators Alexandra F. Kritikos, MA, Brandeis University Cannabis Control Commission Communications Cedric Sinclair, Director of Communications Maryalice Gill, Press Secretary Kirsten Swenson, Communications Specialist Management Alisa Stack, Chief Operating Officer Erika Scibelli, Chief of Staff Legal Christine Baily, General Counsel Allie DeAngelis, Associate General Counsel Enforcement and Licensing Yaw Gyebi, Chief of Enforcement Paul Payer, Enforcement Counsel Kyle Potvin, Director of Licensing Patrick Beyea, Director of Investigations Derek Chamberlin, Licensing Analyst Anne DiMare, Licensing Specialist Government Affairs David Lakeman, Director of Government Affairs 2 Suggested bibliographic reference format: Doonan SM., McKenna, D., Johnson JK., (2020, February). A Baseline Review and Assessment of the Massachusetts Adult-Use Cannabis Industry— A Report to the Massachusetts Legislature. Boston, MA: Massachusetts Cannabis
    [Show full text]